CCL18 and systemic sclerosis: A large prospective trial (n = 427) confirmed these results by showing that a high CCL18 serum baseline value (cut-off 84 pg/mL) (HR = 2.9) and male sex (HR = 2.48) were the best predictors of subsequent lung function decline [138], although the association with SSc-relevant mortality was unclear.